Skip to main content
. 2019 Feb 19;11(2):244. doi: 10.3390/cancers11020244
ADC adenocarcinoma
AP appearance
bg beige mutation
cMDI carcinogen-induced mouse-derived isografts
CRL Charles River Laboratories
DMSO Dimethyl sulfoxide
FACS fluorescence activated cell sorter
FPKM fragments per kilobase million
HS/HAL histiocytic sarcoma//histiocyte-associated lymphoma
ICPI immune checkpoint inhibitors
IFN interferon
IHC immunohistochemistry
IRE internal relative expression
LN lymph node
MCA 3-methylcholanthrene
mCTLA-4 mouse cytotoxic T-lymphocyte-associated protein 4
MDI Mouse-derived isografts
cMDI carcinogen-induced mouse-derived isograft
sMDI spontaneous mouse-derived isograft
MDSC myeloid-derived suppressor cells
macrophage
MHC major histocompatibility complex
M-MDSC monocytic MDSC
MMR macrophage mannose receptor
MNU N-methyl-N-nitrosourea
mPD-1 mouse programmed cell death protein 1
NOD non-obese diabetic
NOD mice non-obese diabetic mice
NOS not otherwise specified
NSG mice NOD SCID gamma mice
PBS phosphate-buffered saline
PDX patient-derived xenografts
RNA ribonucleic acid
RNA-Seq RNA whole transcriptome shotgun sequencing
RPKM reads per kilobase million
RRT real running time
SCID severe combined immunodeficiency disease
SCID mice severe combined immunodeficiency mice
SCID/bg SCID beige mutation
SCID/bg mice severe combined immunodeficiency beige mice
TATA tumor-associated transplantation antigens
Treg regulatory T-cells
TTW treatment time window
UKCCCR United Kingdom Coordinating Committee of Cancer Research